Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells

Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells

US Patent 10842823 · Granted Nov 24, 2020

Estimated economic value: $47,495,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Automated bioreactor system, system for automatically implementing protocol for 2025
Medical body shield2025
Treatment of pulmonary arterial hypertension with prostacyclin-treated endotheli2025
Treatment of pulmonary arterial hypertension with prostacyclin-treated endotheli2025
Treatment of pulmonary arterial hypertension with prostacyclin-treated endotheli2025
Treatment of pulmonary arterial hypertension with prostacyclin-treated endotheli2025
Treatment of vasculopathy with prostacyclin and mesenchymal stem cells2025
Treatment of vasculopathy with prostacyclin and mesenchymal stem cells2025
Treatment of vasculopathy with prostacyclin and mesenchymal stem cells2025
Treatment of vasculopathy with prostacyclin and mesenchymal stem cells2025
Bioactive renal cells2024
Automated bioreactor system, system for automatically implementing protocol for 2024